The quarter had no clean earnings surprise. Avalyn is pre-revenue, and the filing does not provide per-share EPS or a share count needed to substantiate a precise beat or miss. A published EPS estimate near negative $0.66 existed, but the filing’s lack of reported EPS makes that comparison unreliable.
| Metric | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| R&D expense | $24.7M (Financial Results) | $17.9M (Financial Results) | +38% |
| G&A expense | $6.6M (Financial Results) | $3.9M (Financial Results) | +68% |
| Total operating expenses | $31.3M (Income Statement) | $21.8M (Income Statement) | +44% |
| Net loss | $28.9M (Income Statement) | $20.2M (Income Statement) | +43% |
| Cash, equivalents and marketable securities | $413.5M (Balance Sheet Data) | $138.4M at Dec. 31, 2025 (Balance Sheet Data) | +$275.2M |
The substantive update is operational, not financial. MIST completed enrollment with 398 patients, 23 above its 375-patient target, which reduces enrollment risk for AP01. But the trial still runs for 52 weeks and topline data are not expected until the second half of 2027, so this advances the program without resolving its central efficacy question (AP01 — MIST Phase 2b Trial).
The cash position removes near-term financing pressure. Avalyn ended June with $413.5 million, including approximately $316.6 million from its May 2026 IPO, and projects funding into 2029 (Cash Position; Balance Sheet Data). That is a meaningful balance-sheet improvement, but much of it was already visible after the IPO rather than created by this quarter.
The pipeline remains on schedule, not ahead of it. AP02 enrollment is described as on track, with late-2027 data expected, while AP03 remains targeted for a Phase 1 start by the end of 2026 (AP02 — AURA Phase 2 Trial; AP03 — Next-Generation Therapy). The September 2026 ERS presentations may provide supportive tissue-distribution modeling, but they are not clinical efficacy results (Recent Pipeline Progress — AP01).
Net read: operationally reassuring, strategically still waiting. Enrollment completion and the extended runway modestly improve execution confidence, but the filing largely confirms the expected development path and leaves the value-defining evidence—AP01 efficacy and tolerability—until 2027. That supports an in-line scorecard with a mixed underlying signal rather than a clear earnings beat.
Read the original 8-K on SEC EDGAR ↗